These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1020 related articles for article (PubMed ID: 17644538)

  • 1. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
    Chopin F; Garnero P; le Henanff A; Debiais F; Daragon A; Roux C; Sany J; Wendling D; Zarnitsky C; Ravaud P; Thomas T
    Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study.
    Lange U; Teichmann J; Müller-Ladner U; Strunk J
    Rheumatology (Oxford); 2005 Dec; 44(12):1546-8. PubMed ID: 16263785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor {alpha} treatment.
    Briot K; Garnero P; Le Henanff A; Dougados M; Roux C
    Ann Rheum Dis; 2005 Aug; 64(8):1137-40. PubMed ID: 15642695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis.
    Garnero P; Gineyts E; Christgau S; Finck B; Delmas PD
    Arthritis Rheum; 2002 Jan; 46(1):21-30. PubMed ID: 11817593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis.
    Torikai E; Kageyama Y; Takahashi M; Suzuki M; Ichikawa T; Nagafusa T; Nagano A
    Rheumatology (Oxford); 2006 Jun; 45(6):761-4. PubMed ID: 16436492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456].
    Forsblad d'Elia H; Christgau S; Mattsson LA; Saxne T; Ohlsson C; Nordborg E; Carlsten H
    Arthritis Res Ther; 2004; 6(5):R457-68. PubMed ID: 15380045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Periarticular bone gain at proximal interphalangeal joints and changes in bone turnover markers in response to tumor necrosis factor inhibitors in rheumatoid and psoriatic arthritis.
    Szentpetery A; McKenna MJ; Murray BF; Ng CT; Brady JJ; Morrin M; Radovits B; Veale DJ; Fitzgerald O
    J Rheumatol; 2013 May; 40(5):653-62. PubMed ID: 23457381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis.
    Seriolo B; Paolino S; Sulli A; Ferretti V; Cutolo M
    Ann N Y Acad Sci; 2006 Jun; 1069():420-7. PubMed ID: 16855169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis.
    Charni N; Juillet F; Garnero P
    Arthritis Rheum; 2005 Apr; 52(4):1081-90. PubMed ID: 15818703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How useful are bone turnover markers in rheumatoid arthritis? Influence of disease activity and corticosteroid therapy.
    Cortet B; Flipo RM; Pigny P; Duquesnoy B; Racadot A; Boersma A; Delcambre B
    Rev Rhum Engl Ed; 1997 Mar; 64(3):153-9. PubMed ID: 9090763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab.
    Marotte H; Pallot-Prades B; Grange L; Gaudin P; Alexandre C; Miossec P
    Arthritis Res Ther; 2007; 9(3):R61. PubMed ID: 17597527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.
    Rogers A; Glover SJ; Eastell R
    Bone; 2009 Dec; 45(6):1044-52. PubMed ID: 19665601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.
    Maksymowych WP; Poole AR; Hiebert L; Webb A; Ionescu M; Lobanok T; King L; Davis JC
    J Rheumatol; 2005 Oct; 32(10):1911-7. PubMed ID: 16206346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis.
    Güler-Yüksel M; Bijsterbosch J; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; Hulsmans HM; de Beus WM; Han KH; Breedveld FC; Dijkmans BA; Allaart CF; Lems WF
    Ann Rheum Dis; 2008 Jun; 67(6):823-8. PubMed ID: 17644545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is bone turnover a determinant of bone mass in rheumatoid arthritis?
    Cortet B; Flipo RM; Pigny P; Duquesnoy B; Boersma A; Marchandise X; Delcambre B
    J Rheumatol; 1998 Dec; 25(12):2339-44. PubMed ID: 9858427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis.
    Güler-Yüksel M; Allaart CF; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; van Groenendael JH; Mallée C; de Bois MH; Breedveld FC; Dijkmans BA; Lems WF
    Ann Rheum Dis; 2009 Mar; 68(3):330-6. PubMed ID: 18375540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes of cartilage and bone markers after intra-articular glucocorticoid treatment with and without postinjection rest in patients with rheumatoid arthritis.
    Weitoft T; Larsson A; Saxne T; Rönnblom L
    Ann Rheum Dis; 2005 Dec; 64(12):1750-3. PubMed ID: 15843449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
    Lequerré T; Jouen F; Brazier M; Clayssens S; Klemmer N; Ménard JF; Mejjad O; Daragon A; Tron F; Le Loët X; Vittecoq O
    Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short term whole body retention in relation to rate of bone resorption and cartilage degradation after intravenous bisphosphonate (pamidronate) in rheumatoid arthritis.
    Cremers SC; Lodder MC; Den Hartigh J; Vermeij P; Van Pelt P; Lems WF; Papapoulos SE; Dijkmans BA
    J Rheumatol; 2004 Sep; 31(9):1732-7. PubMed ID: 15338492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone.
    Han KO; Choi JT; Choi HA; Moon IG; Yim CH; Park WK; Yoon HK; Han IK
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):349-53. PubMed ID: 15730418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.